H. R. 4365—135
of which $3,000,000 shall be available for activities under para-
graphs (5) through (8) of subsection (a) and for employing personnel
in positions established under subsection (b)(2).
PART III—ABUSE PREVENTION AND
TREATMENT
SEC. 3631. EXPANSION OF METHAMPHETAMINE RESEARCH.
Section 464N of the Public Health Service Act (42 U.S.C. 285o–
2) is amended by adding at the end the following:
‘‘(c) METHAMPHETAMINE RESEARCH.—
‘‘(1) GRANTS OR COOPERATIVE AGREEMENTS.—The Director
of the Institute may make grants or enter into cooperative
agreements to expand the current and on-going interdiscipli-
nary research and clinical trials with treatment centers of
the National Drug Abuse Treatment Clinical Trials Network
relating to methamphetamine abuse and addiction and other
biomedical, behavioral, and social issues related to meth-
amphetamine abuse and addiction.
‘‘(2) USE
OF
FUNDS.—Amounts made available under a
grant or cooperative agreement under paragraph (1) for meth-
amphetamine abuse and addiction may be used for research
and clinical trials relating to—
‘‘(A) the effects of methamphetamine abuse on the
human body, including the brain;
‘‘(B) the addictive nature of methamphetamine and
how such effects differ with respect to different individuals;
‘‘(C) the connection between methamphetamine abuse
and mental health;
‘‘(D) the identification and evaluation of the most effec-
tive methods of prevention of methamphetamine abuse and
addiction;
‘‘(E) the identification and development of the most
effective methods of treatment of methamphetamine addic-
tion, including pharmacological treatments;
‘‘(F) risk factors for methamphetamine abuse;
‘‘(G) effects of methamphetamine abuse and addiction
on pregnant women and their fetuses; and
‘‘(H) cultural, social, behavioral, neurological and
psychological reasons that individuals abuse methamphet-
amine, or refrain from abusing methamphetamine.
‘‘(3) RESEARCH
RESULTS.—The Director shall promptly
disseminate research results under this subsection to Federal,
State and local entities involved in combating methamphet-
amine abuse and addiction.
‘‘(4) AUTHORIZATION OF APPROPRIATIONS.—
‘‘(A) AUTHORIZATION
OF
APPROPRIATIONS.—There is
authorized to be appropriated to carry out paragraph (1),
such sums as may be necessary for each fiscal year.
‘‘(B) SUPPLEMENT
NOT
SUPPLANT.—Amounts appro-
priated pursuant to the authorization of appropriations
in subparagraph (A) for a fiscal year shall supplement
and not supplant any other amounts appropriated in such
fiscal year for research on methamphetamine abuse and
addiction.’’.
H. R. 4365—136
SEC. 3632. METHAMPHETAMINE AND AMPHETAMINE TREATMENT INI-
TIATIVE BY CENTER FOR SUBSTANCE ABUSE TREAT-
MENT.
Subpart 1 of part B of title V of the Public Health Service
Act (42 U.S.C. 290bb et seq.) is amended by adding at the end
the following new section:
‘‘METHAMPHETAMINE AND AMPHETAMINE TREATMENT INITIATIVE
‘‘SEC. 514. (a) GRANTS.—
‘‘(1) AUTHORITY
TO
MAKE
GRANTS.—The Director of the
Center for Substance Abuse Treatment may make grants to
States and Indian tribes recognized by the United States that
have a high rate, or have had a rapid increase, in methamphet-
amine or amphetamine abuse or addiction in order to permit
such States and Indian tribes to expand activities in connection
with the treatment of methamphetamine or amphetamine
abuser or addiction in the specific geographical areas of such
States or Indian tribes, as the case may be, where there is
such a rate or has been such an increase.
‘‘(2) RECIPIENTS.—Any grants under paragraph (1) shall
be directed to the substance abuse directors of the States,
and of the appropriate tribal government authorities of the
Indian tribes, selected by the Director to receive such grants.
‘‘(3) NATURE OF ACTIVITIES.—Any activities under a grant
under paragraph (1) shall be based on reliable scientific evi-
dence of their efficacy in the treatment of methamphetamine
or amphetamine abuse or addiction.
‘‘(b) GEOGRAPHIC DISTRIBUTION.—The Director shall ensure that
grants under subsection (a) are distributed equitably among the
various regions of the country and among rural, urban, and subur-
ban areas that are affected by methamphetamine or amphetamine
abuse or addiction.
‘‘(c) ADDITIONAL ACTIVITIES.—The Director shall—
‘‘(1) evaluate the activities supported by grants under sub-
section (a);
‘‘(2) disseminate widely such significant information derived
from the evaluation as the Director considers appropriate to
assist States, Indian tribes, and private providers of treatment
services for methamphetamine or amphetamine abuser or
addiction in the treatment of methamphetamine or amphet-
amine abuse or addiction; and
‘‘(3) provide States, Indian tribes, and such providers with
technical assistance in connection with the provision of such
treatment.
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—
‘‘(1) IN GENERAL.—There are authorized to be appropriated
to carry out this section $10,000,000 for fiscal year 2000 and
such sums as may be necessary for each of fiscal years 2001
and 2002.
‘‘(2) USE OF CERTAIN FUNDS.—Of the funds appropriated
to carry out this section in any fiscal year, the lesser of 5
percent of such funds or $1,000,000 shall be available to the
Director for purposes of carrying out subsection (c).’’.
SEC. 3633. STUDY OF METHAMPHETAMINE TREATMENT.
(a) STUDY.—
H. R. 4365—137
(1) REQUIREMENT.—The Secretary of Health and Human
Services shall, in consultation with the Institute of Medicine
of the National Academy of Sciences, conduct a study on the
development of medications for the treatment of addiction to
amphetamine and methamphetamine.
(2) REPORT.—Not later than 9 months after the date of
the enactment of this Act, the Secretary shall submit to the
Committees on the Judiciary of the Senate and House of Rep-
resentatives a report on the results of the study conducted
under paragraph (1).
(b) AUTHORIZATION
OF APPROPRIATIONS.—There are hereby
authorized to be appropriated for the Department of Health and
Human Services for fiscal year 2000 such sums as may be necessary
to meet the requirements of subsection (a).
PART IV—REPORTS
SEC. 3641. REPORTS ON CONSUMPTION OF METHAMPHETAMINE AND
OTHER ILLICIT DRUGS IN RURAL AREAS, METROPOLITAN
AREAS, AND CONSOLIDATED METROPOLITAN AREAS.
The Secretary of Health and Human Services shall include
in each National Household Survey on Drug Abuse appropriate
prevalence data and information on the consumption of meth-
amphetamine and other illicit drugs in rural areas, metropolitan
areas, and consolidated metropolitan areas.
SEC. 3642. REPORT ON DIVERSION OF ORDINARY, OVER-THE-COUNTER
PSEUDOEPHEDRINE 
AND 
PHENYLPROPANOLAMINE
PRODUCTS.
(a) STUDY.—The Attorney General shall conduct a study of
the use of ordinary, over-the-counter pseudoephedrine and phenyl-
propanolamine products in the clandestine production of illicit
drugs. Sources of data for the study shall include the following:
(1) Information from Federal, State, and local clandestine
laboratory seizures and related investigations identifying the
source, type, or brand of drug products being utilized and
how they were obtained for the illicit production of meth-
amphetamine and amphetamine.
(2) Information submitted voluntarily from the pharma-
ceutical and retail industries involved in the manufacture, dis-
tribution, and sale of drug products containing ephedrine,
pseudoephedrine, and phenylpropanolamine, including informa-
tion on changes in the pattern, volume, or both, of sales of
ordinary, 
over-the-counter 
pseudoephedrine 
and 
phenyl-
propanolamine products.
(b) REPORT.—
(1) REQUIREMENT.—Not later than 1 year after the date
of the enactment of this Act, the Attorney General shall submit
to Congress a report on the study conducted under subsection
(a).
(2) ELEMENTS.—The report shall include—
(A) the findings of the Attorney General as a result
of the study; and
(B) such recommendations on the need to establish
additional measures to prevent diversion of ordinary, over-
the-counter pseudoephedrine and phenylpropanolamine
(such as a threshold on ordinary, over-the-counter
H. R. 4365—138
pseudoephedrine and phenylpropanolamine products) as
the Attorney General considers appropriate.
(3) MATTERS CONSIDERED.—In preparing the report, the
Attorney General shall consider the comments and rec-
ommendations including the comments on the Attorney Gen-
eral’s proposed findings and recommendations, of State and
local law enforcement and regulatory officials and of representa-
tives of the industry described in subsection (a)(2).
(c) REGULATION OF RETAIL SALES.—
(1) IN
GENERAL.—Notwithstanding section 401(d) of the
Comprehensive Methamphetamine Control Act of 1996 (21
U.S.C. 802 note) and subject to paragraph (2), the Attorney
General shall establish by regulation a single-transaction limit
of not less than 24 grams of ordinary, over-the-counter
pseudoephedrine or phenylpropanolamine (as the case may be)
for retail distributors, if the Attorney General finds, in the
report under subsection (b), that—
(A) there is a significant number of instances (as set
forth in paragraph (3)(A) of such section 401(d) for purposes
of 
such 
section) 
where 
ordinary, 
over-the-counter
pseudoephedrine products, phenylpropanolamine products,
or both such products that were purchased from retail
distributors were widely used in the clandestine production
of illicit drugs; and
(B) the best practical method of preventing such use
is the establishment of single-transaction limits for retail
distributors of either or both of such products.
(2) DUE PROCESS.—The Attorney General shall establish
the single-transaction limit under paragraph (1) only after
notice, comment, and an informal hearing.
Subtitle B—Controlled Substances
Generally
SEC. 3651. ENHANCED PUNISHMENT FOR TRAFFICKING IN LIST I
CHEMICALS.
(a) AMENDMENTS
TO
FEDERAL
SENTENCING
GUIDELINES.—
Pursuant to its authority under section 994(p) of title 28, United
States Code, the United States Sentencing Commission shall amend
the Federal sentencing guidelines in accordance with this section
with respect to any violation of paragraph (1) or (2) of section
401(d) of the Controlled Substances Act (21 U.S.C. 841(d)) involving
a list I chemical and any violation of paragraph (1) or (3) of
section 1010(d) of the Controlled Substance Import and Export
Act (21 U.S.C. 960(d)) involving a list I chemical.
(b) 
EPHEDRINE, 
PHENYLPROPANOLAMINE, 
AND
PSEUDOEPHEDRINE.—
(1) IN GENERAL.—In carrying this section, the United States
Sentencing Commission shall, with respect to each offense
described in subsection (a) involving ephedrine, phenyl-
propanolamine, or pseudoephedrine (including their salts,
optical isomers, and salts of optical isomers), review and amend
its guidelines to provide for increased penalties such that those
penalties corresponded to the quantity of controlled substance
that could reasonably have been manufactured using the